In addition, prostate specific membrane antigen (PSMA) PET, currently approved for imaging tumor cells in prostate cancer, has been also been studied in breast cancer as a marker of neovascularity, given PSMA expression in endothelial cells [154]. This evidence concerns the gene FOLH1 and breast carcinoma.